Format

Send to

Choose Destination
See comment in PubMed Commons below
BMC Clin Pharmacol. 2009 Oct 23;9:17. doi: 10.1186/1472-6904-9-17.

Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results.

Author information

1
Division of Basic Medical Sciences, Southwest College of Naturopathic Medicine, Tempe, AZ, USA. jim.adams@asu.edu

Abstract

BACKGROUND:

This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years.

METHODS:

Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.

RESULTS:

The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94).

CONCLUSION:

Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.

PMID:
19852790
PMCID:
PMC2770991
DOI:
10.1186/1472-6904-9-17
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center